Lasa Supergenerics Limited (LASA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.59 Million ≈ $27.98K USD) by net assets (Rs563.42 Million ≈ $6.09 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LASA net asset quality score to measure how much of total assets are equity-financed.
Lasa Supergenerics Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Lasa Supergenerics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LASA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Lasa Supergenerics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lasa Supergenerics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stellar AfricaGold Inc.
V:SPX
|
-0.152x |
|
Kuniko Ltd
AU:KNI
|
-0.069x |
|
Komarkcorp Bhd
KLSE:7017
|
0.010x |
|
Indo Pureco Pratama Tbk PT
JK:IPPE
|
0.000x |
|
Yu Group PLC
LSE:YU
|
0.203x |
|
TwentyFour Select Monthly Income Fund Ltd
LSE:SMIF
|
0.045x |
|
Elixirr International Plc
LSE:ELIX
|
0.160x |
|
Novra Technologies Inc
V:NVI
|
-0.231x |
Annual Cash Flow Conversion Efficiency for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Lasa Supergenerics Limited from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see LASA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs837.13 Million ≈ $9.05 Million |
Rs-28.24 Million ≈ $-305.37K |
-0.034x | -252.47% |
| 2024-03-31 | Rs966.76 Million ≈ $10.46 Million |
Rs21.39 Million ≈ $231.29K |
0.022x | +115.13% |
| 2023-03-31 | Rs1.18 Billion ≈ $12.79 Million |
Rs-173.00 Million ≈ $-1.87 Million |
-0.146x | -350.68% |
| 2022-03-31 | Rs1.58 Billion ≈ $17.07 Million |
Rs92.12 Million ≈ $996.20K |
0.058x | -77.56% |
| 2021-03-31 | Rs1.59 Billion ≈ $17.19 Million |
Rs413.10 Million ≈ $4.47 Million |
0.260x | +169.95% |
| 2020-03-31 | Rs1.41 Billion ≈ $15.30 Million |
Rs136.23 Million ≈ $1.47 Million |
0.096x | -75.06% |
| 2019-03-31 | Rs1.05 Billion ≈ $11.39 Million |
Rs406.58 Million ≈ $4.40 Million |
0.386x | +12.48% |
| 2018-03-31 | Rs1.17 Billion ≈ $12.69 Million |
Rs402.80 Million ≈ $4.36 Million |
0.343x | +962.97% |
| 2017-03-31 | Rs754.94 Million ≈ $8.16 Million |
Rs-30.03 Million ≈ $-324.76K |
-0.040x | -- |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more